Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorConsorci Sanitari de Terrassa
About this trial
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.
Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.
The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
Eligibility criteria
Qualifiers
Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.
Disqualifiers
None.
For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.
Trial design
Treatments tested in this trial
- Antihistamine
- Amantadine
- ACEI
- ARB
- Influenza vaccine and COVID
Treatment groups
3,000 Participants
are divided into 3 treatment groupsSponsors and collaborators
Consorci Sanitari de Terrassa
Lead sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Collaborator
Institut Català de la Salut
Collaborator
Source ClinicalTrials.gov